Clinical Trial Update: Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial aimed to determine the dose of recombinant human hyaluronidase needed to infuse a full dose of intravenous immunoglobulin subcutaneously, condu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• IGIV
• Recombinant human hyaluronidase (recombinant human hyaluronidase (rHuPH20))

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 1, Phase 2 | Status: COMPLETED